comparison of glp-1 agonists Comparing GLP-type therapies for weight loss in those without diabetes. Two glucagon-like peptide-1 receptor (GLP-1 RAs) (#semaglutide and #liraglutide) and one dual agonist (#tirzepatide) have been FDA-approved for #weightloss in adults GLP-1 RECEPTORS AGONISTS Comparisons among

Patients with indicators of high-risk or established ASCVD, chronic kidney disease, or heart failure According to the ADA, when considering an agent for add-on to metformin background therapy, the first recommended consideration is whether or not the patient has indicators of high-risk or established ASCVD, chronic kidney disease (CKD), or heart failure ( Figure 2 )

And when side effects persist beyond the typical 4-6 week adjustment period, switching to an alternative with a different receptor binding profile or mechanism of action often resolves the issue entirely

Sudden inflammation of the pancreas may occur with these medications, though it is rare

Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity

With insulin resistance, common in people with excess adiposity, prediabetes, and type 2 diabetes, glucagon and insulin levels may be elevated